Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)

Clinical Infectious Diseases(2022)10.1093/cid/ciac707Source: DataRank Database

Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349) is a research paper published in Clinical Infectious Diseases (2022). On theSindex it has a DataRank of 0.726. It has been cited 13 times, with 11 citing works in its 1-hop citation network.

N/A

0.726DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access13 citations · 11 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02410772

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (23 grants)Impact (FWCI 1.26)OA: hybridTopics (50)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 55%Citation Network 45%

Base Score Contribution

0.396

From this paper's citation signal

Citation Network Contribution

0.330

From 11 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 11 citers.

Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition)
Chinese Medical Journal202479 citations42 referencesContributes 0.104
Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition)
Infectious Diseases & Immunity20248 citations37 referencesContributes 0.059
Singapore tuberculosis (TB) clinical management guidelines 2024: A modified Delphi adaptation of international guidelines for drug-susceptible TB infection and pulmonary disease
Annals of the Academy of Medicine Singapore20245 citations34 referencesContributes 0.053
Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database
Frontiers in Pharmacology20254 citations45 referencesContributes 0.036
Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management
Current Opinion in Pulmonary Medicine202412 citations74 referencesContributes 0.035